Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

AIDS

Volumn 15, Issue 13, 2001, Pages 1701-1706

  Gallego, Oscar ^a   De Mendoza, Carmen ^a   Pérez Elías, María Jesús ^b   Guardiola, Josep María ^c   Pedreira, José ^d   Dalmau, David ^e   Gónzalez, Juan ^f   Moreno, Ana ^b   Arribas, José Ramón ^f   Rubio, Amalia ^g   García Arata, Isabel ^a   Leal, Manuel ^g   Domingo, Pere ^c   Soriano, Vincent ^a,h  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h NONE   (Spain)

Author keywords

Drug resistance; Indinavir; Virologic failure

Indexed keywords

INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; STAVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INDINAVIR; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 0035823002     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109070-00014     Document Type: Article

References (34)

1. Antiretroviral therapy in adults: Update recommendations of the International AIDS Society-USA Panel
2. Drug resistance testing: Time to be used in clinical practice?
3. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from EuroSIDA study
4. HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
5. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
6. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
7. Drug susceptibility on HIV infection after viral rebounds in patients receiving indinavir-containing regimens
8. Early virological failure in naive HIV patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance
9. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
10. Replicatlve fitness of protease inhibitor-resistant mutants of HIV type 1
11. Low level of cross-resistance to amprenavir (141W94) in samples from patients pre-treated with other protease inhibitors
12. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
13. Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor
14. Mutation in retroviral genes associated with drug resistance: 2000-2001 Update
15. A branched DNA signal amplification assay for quantitation of nucleic acid targets below 100 molecules/ml
16. Isolation of HIV-RNA from plasma: Evaluation of eight different extraction methods
17. Antiretroviral drug resistance testing in adults HIV-1 infection
18. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The ACTG adherence instruments
19. A novel HIV-1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
20. Introduction of HIV drug resistance testing in clinical practice
21. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
22. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
23. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
24. Clinical pharmacokinetics of antiretroviral drugs
25. HIV-1 protease inhibitors are substrates for the MDR1 mutidrug transporter
26. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
27. Protease inhibitors - Mechanisms and clinical aspects
28. Kinetic characterisation and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
29. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
30. Second Spanish consensus on the use of drug resistance testing in clinical practice
31. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples
32. Efficiency of drug resistance genotypic tests in specimens with low HIV viral load
33. HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations
34. Intensification of antiretroviral therapy